Global Bovine Respiratory Disease Treatment Market Report and Forecast 2024-2032

Global Bovine Respiratory Disease Treatment Market Outlook

The global bovine respiratory disease treatment market is estimated to develop at a CAGR of 11.5% during 2024-2032. Bovine respiratory disease is a generic term for respiratory disease in cattle triggered by multiple factors, either individually or collectively. Bovine respiratory disease may attack the lower or upper respiratory tract. North America and Europe are likely to be significant markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Market Likely to be Driven by the Need to Effectively Treat Bovine Respiratory Disease

Bovine respiratory disease is a damaging disease that affects cattle health and leads to high mortality. In fact, the disease is a key cause of death in preweaned calves in USA and is behind almost fifty percent of total feedlot deaths. Bovine respiratory disease touches more animals than all other ailments collectively and costs the industry over $550 million per year. In Europe, bovine respiratory disease is a major source of morbidity and mortality of dairy youngstock and beef cattle.

Bovine respiratory disease may be triggered by pathogens – viral as well as bacterial. Stress contributes to the disease complex. Stress factors include humidity, weather, change in temperature, weaning, change of feed, etc. Clinical symptoms rely on several factors such as animal age, stage of disease and causative organism. Symptoms include fever; depression; reduced appetite; dullness; shallow and rapid breathing; coughing; serous, purulent or bloody eye and nasal release; and salivation.

Many virus and bacteria strains may trigger the disease, making it challenging to treat effectively. Treatment is particularly directed to the illness and the indications. Medication may include anti-infectious agents (Sulfas and Antibiotics), antiparasiticides, non-steroidal anti-inflammatories, mucolytics, bronchodilators, oral rehydration fluids. Several antimicrobial drugs are indicated to treat bovine respiratory disease. Drugs such as florfenicol, tulathromycin, enrofloxacin, and danofloxacin have been reported to display similar effectiveness in treating the condition. However, antimicrobial resistance associated with the use of these drugs is an important consideration.

Nonsteroidal anti-inflammatories (NSAIDs) (combined with an antimicrobial drug) are generally indicated to treat the condition. Such an approach has also been suggested to improve animal growth.

There are Serious Economic Consequences Associated with the Condition

Bovine respiratory disease has serious economic impacts. In the American beef industry, the disease is a leading source of mortality and morbidity in feedlots, leading to loss in performance, health, and quality of carcass. The dairy industry in the US is significantly affected by bovine respiratory disease as the ailment forms a key cause of death in weaned calves; bovine respiratory disease impacts survivability and decreases dairy performance.  Economic losses include loss due to death, reduced weight and decreased rate of weight gain, and extra labour and treatment costs.

Developments in Research Expected to Boost Market Growth

Continual research is being carried out in the domain to develop novel solutions. For example, in 2021, it was reported that a pen-side test developed for bovine respiratory disease could help save significant amounts of money for the cattle industry, and decrease antibiotic use. Researchers at Purdue University were successful in developing an on-site bovine respiratory disease test that gave results within one hour. The new technology could identify three (Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni) of the top four bacterial strains that triggered bovine respiratory disease. Such developments are likely to drive the global bovine respiratory disease treatment market.

In 2023, it was reported that a multidisciplinary research team was engaged in developing rapid genomic testing methods to change how feedlots decided about antimicrobial use and enhance antimicrobial stewardship. Researchers and scientists leading Genomic ASSETS (Antimicrobial Stewardship Systems from Evidence-Based Treatment Strategies) for Livestock  sought to develop rapid testing technology to determine respiratory pathogens and antimicrobial resistance in calves coming into feedlots to develop group-level, precision antibiotic treatment.

Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By disease type, the market is segmented into:

• Pneumonia (Lower Respiratory Tract Infections)

• Diphtheria

• Upper Respiratory Tract Infections

By drug type, the market is divided into:

• Antibiotics

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

• Vaccines

• Immunomodulators

• Others

By end use, the market is classified into:

• Veterinary Hospitals

• Veterinary Clinics

• Others

By region, the market is divided into:

• Europe

• Asia Pacific

• North America

• Middle East and Africa

• Latin America

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Market

The report gives a comprehensive assessment of major players in the global bovine respiratory disease treatment market, evaluating their capacity, and observing newest developments such as mergers and acquisitions, plant turnarounds, and capacity expansions; major players include:

• Boehringer Ingelheim International GmbH

• Elanco Animal Health Incorporated

• Zoetis Services LLC.

• Ceva Santé Animale

• Norbrook Group

• Others

The EMR report offers in-depth insights into the industry by through a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report